Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Cyclacel Pharmaceuticals Inc (CYCC) USD0.01

Sell:$5.50 Buy:$5.97 Change: $0.61 (8.28%)
Market closed |  Prices as at close on 4 March 2021 | Switch to live prices |
Sell:$5.50
Buy:$5.97
Change: $0.61 (8.28%)
Market closed |  Prices as at close on 4 March 2021 | Switch to live prices |
Sell:$5.50
Buy:$5.97
Change: $0.61 (8.28%)
Market closed |  Prices as at close on 4 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Contact details

Address:
200 Connell Dr Ste 1500
BERKELEY HEIGHTS
07922-2811
United States
Telephone:
+1 (908) 5177330
Website:
www.cyclacel.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CYCC
ISIN:
US23254L6039
Market cap:
$48.02 million
Shares in issue:
7.10 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • David U'Prichard
    Independent Chairman of the Board
  • Spiro Rombotis
    President, Chief Executive Officer, Director
  • Christopher Henney
    Independent Vice Chairman of the Board
  • Paul McBarron
    Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
  • Mark Kirschbaum
    Senior Vice President, Chief Medical Officer
  • Judy Chiao
    Vice President - Clinical Development and Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.